Key result
Heparin and nonanticoagulant heparin reduce ischemia-reperfusion injury by disrupting inflammatory cascades and NF-kappaB activation.
Why the study?
Does heparin or nonanticoagulant heparin reduce ischemia-reperfusion injury in preclinical models of myocardial infarction?
Does heparin or nonanticoagulant heparin reduce ischemia-reperfusion injury in preclinical models of myocardial infarction?
Heparin and nonanticoagulant heparin attenuate myocardial ischemia-reperfusion injury by inhibiting NF-kappaB activation, independent of anticoagulant or anticomplement activity.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating in animal models; leaves open clinical translation and should not alter practice.
Thourani et al. (2000) studied Myocardial ischemia-reperfusion injury. Heparin and o-desulfated nonanticoagulant heparin was evaluated on Neutrophil adherence, myocardial necrosis, creatine kinase release, and NF-kappaB activation. Heparin and nonanticoagulant heparin decreased ischemia-reperfusion injury by disrupting multiple levels of the inflammatory cascade, including inhibiting NF-kappaB activation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: